Sunil Gandhi

Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma

B. Sangro, Stephen L. Chan, Robin Kate Kelley et al. · Annals of Oncology · 2024 · 312 citations · Full text

Medicine, Oncology, Pharmacotherapy +16

Phase 1/2 study of ARV-110, an androgen receptor (AR) PROTAC degrader, in metastatic castration-resistant prostate cancer (mCRPC).

Xīn Gào, Howard A. Burris, Jacqueline Vuky et al. · Journal of Clinical Oncology · 2022 · 186 citations

Medicine, Oncology, Pharmacology +16

Efficacy and Safety of Telaglenastat Plus Cabozantinib vs Placebo Plus Cabozantinib in Patients With Advanced Renal Cell Carcinoma

Nizar M. Tannir, Neeraj Agarwal, Camillo Porta et al. · JAMA Oncology · 2022 · 142 citations · Full text

Medicine, Oncology, Pharmacology +17

A randomized, double-blind, placebo-controlled phase 2 study evaluating the efficacy and safety of romiplostim treatment of patients with low or intermediate-1 risk myelodysplastic syndrome receiving lenalidomide

Eunice S. Wang, Roger M. Lyons, Sunil Gandhi et al. · Journal of Hematology & Oncology · 2012 · 63 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

CANTATA: Primary analysis of a global, randomized, placebo (Pbo)-controlled, double-blind trial of telaglenastat (CB-839) + cabozantinib versus Pbo + cabozantinib in advanced/metastatic renal cell carcinoma (mRCC) patients (pts) who progressed on immune checkpoint inhibitor (ICI) or anti-angiogenic therapies.

Nizar M. Tannir, Neeraj Agarwal, Camillo Porta et al. · Journal of Clinical Oncology · 2021 · 42 citations

Medicine, Oncology, Pharmacology +6